Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Energenesis Biomedical CoTPE:6657 -0.69%68 PB Ratio is 3.52 as of Jul. 22, 2026, which is 34% below its 10-year median of 5.30. GuruFocus rates TPE:6657 with a GF Score™ of 68/100 and a GF Value™ of NT$51.50 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,229 Biotechnology companies, Energenesis Biomedical Co ranks worse than 59.07% on this metric.
Energenesis Biomedical Co Ltd stock PB Ratio (=3.33) is close to 5-year low of 3.26.
The historical rank and industry rank for Energenesis Biomedical Co's PB Ratio or its related term are showing as below:
TPE:6657'
s PB Ratio Range Over the Past 10 Years
Min: 3.26 Med: 5.3 Max: 8.28
Current: 3.52
During the past 11 years, Energenesis Biomedical Co's highest PB Ratio was 8.28. The lowest was 3.26. And the median was 5.30.
TPE:6657's PB Ratio is ranked worse than 59.07% of 1229
companies
in the Biotechnology industry
Industry Median: 2.82
vs TPE:6657: 3.52
During the past 12 months, Energenesis Biomedical Co's average Book Value Per Share Growth Rate was 6.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -3.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 14.50% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Energenesis Biomedical Co was 85.40% per year. The lowest was -12.30% per year. And the median was 8.45% per year.
Back to Basics: PB Ratio
Energenesis Biomedical Co (TPE:6657) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Energenesis Biomedical Co PB Ratio Related Terms
Energenesis Biomedical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Energenesis Biomedical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Energenesis Biomedical Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Energenesis Biomedical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Energenesis Biomedical Co (TPE:6657) has a PB Ratio of 3.52 as of Jul. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Energenesis Biomedical Co and its competitors. This is 34% below median its historical median of 5.30. Over the past decade, Energenesis Biomedical Co's PB Ratio has ranged from 3.26 to 8.28. According to the industry distribution chart, Energenesis Biomedical Co ranks #726 out of 1229 companies in the Biotechnology industry, placing it in the top 59.1%.
Is Energenesis Biomedical Co's PB Ratio too high?
Energenesis Biomedical Co's current PB Ratio of 3.52 is 34% below median its 10-year median of 5.30. Over the past 10 years, this metric has ranged from a low of 3.26 to a high of 8.28. The Biotechnology industry median PB Ratio is 2.82. Energenesis Biomedical Co's value of 3.52 is 24.8% above this industry median. Based on the distribution chart, Energenesis Biomedical Co ranks #726 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Energenesis Biomedical Co has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Energenesis Biomedical Co ranks #726 out of 1229 companies for PB Ratio. This places Energenesis Biomedical Co in the lower half of its industry. The industry median PB Ratio is 2.82. Energenesis Biomedical Co's value of 3.52 is 24.8% above this benchmark. Historically, Energenesis Biomedical Co's own PB Ratio has ranged from 3.26 to 8.28 over the past decade. While the company's 10-year median is 5.30 vs. the industry median of 2.82, Energenesis Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Energenesis Biomedical Co's current PB Ratio of 3.52 is 24.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Energenesis Biomedical Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Energenesis Biomedical Co's current PB Ratio is 3.52, which is 34% below median its own 10-year median of 5.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.50, compared to a current price of NT$35.85 — trading 30.4% below its estimated fair value. The current PB Ratio is 3.52, which is 34% below median its 10-year median of 5.30 and 24.8% above the Biotechnology industry median of 2.82. Energenesis Biomedical Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current PB Ratio is 3.52 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?
Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued.
The current stock price of NT$35.85 is trading 30.4% below its estimated GF Value™ of NT$51.50.
GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.
Key valuation signals for TPE:6657:
PB Ratio: 3.52 (34% below median its 10-year median of 5.30)
GF Value™: NT$51.50 vs. price of NT$35.85 (30.4% below fair value)
Industry Position: 24.8% above the Biotechnology median (#726 of 1229)
No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
68GF Score
Get the complete analysis for TPE:6657
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6657 has been successfully added to your 
